DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies
News 07.01.2026 Cologne, Germany, January 7, 2026 – DISCO Pharmaceuticals (“DISCO”), today announced an exclusive license agreement with Amgen to advance novel therapeutic candidates addressing a target that was mapped on the surface of a cancer cell by DISCO’s proprietary platform. Under the terms of the agreement, DISCO will be eligible to receive up...